25th Jun 2014 13:28
LONDON (Alliance News) - Akers Biosciences Inc said Wednesday that it had inked a distribution agreement for its PIFA Heparin/PF4 and PIFA PLUSS PF4 test kits with Medline Industries Inc.
Under the agreement Medline will begin marketing the tests over its network of hospitals and surgery centres across the US. The company's sales representatives will visit hospitals and market to multiple hospital departments, which Akers believes will increase the market penetration of the products.
The tests check for heparin-induced thrombocytopenia, which may occur if a patient develops an allergy to the blood thinning drug heparin.
No financial details of the agreement were disclosed.
Shares in Akers were trading up 17% at 315.00 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
AKR.L